Vericel Corp (VCEL) - Form 8-K Summary
Business Context and Reporting Period
Vericel Corporation filed this Current Report on Form 8-K on January 14, 2025, in connection with its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The filing provides preliminary, unaudited estimates of operating and financial results for the fiscal year ended December 31, 2024, along with updated 2025 financial guidance and increased mid-term profitability targets.
Key Financial Metrics
The filing references a press release and corporate presentation containing specific preliminary data points for 2024, including full-year revenue, adjusted EBITDA, adjusted EBITDA margin, gross margin percentage, net income, and cash, restricted cash, and investments balances as of December 31, 2024. However, the specific numerical values for these metrics are not included in the text of this Form 8-K; they are contained within the attached exhibits (Exhibit 99.1 and Exhibit 99.2).
Material Changes and Comparisons
The filing indicates that the Company has announced increased mid-term profitability targets. Specific quantitative comparisons between the preliminary 2024 results and the prior comparable period are not detailed in the body of this report and must be derived from the referenced press release and presentation.
Guidance, Outlook, and Risks
- Guidance: The Company has issued 2025 financial guidance and updated mid-term profitability targets.
- Unusual Items/Contingencies: The financial data presented is preliminary, unaudited, and subject to change. Actual results may differ materially from these estimates.
- Disclaimer: PricewaterhouseCoopers LLP has not audited, reviewed, or examined the preliminary financial data and expresses no opinion on it.
- Legal Status: The information in Items 2.02 and 7.01 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific 2024 revenue, net income, and cash balance figures.
- Review Exhibit 99.2 (Corporate Presentation) for detailed 2025 guidance and mid-term target specifics.
- Verify the final audited financial statements for 2024 when issued, as current figures are preliminary estimates.
- Confirm the reconciliation of non-GAAP measures (adjusted EBITDA) in the accompanying materials.